SCHEMBL2009779

SCHEMBL2009779

CCOC(=O)COc1ccc(O)c(C(=O)CBr)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.55
GAA P10253 4/20 0.50
HSD17B10 Q99714 4/20 0.50
KDM4E B2RXH2 3/20 0.50
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
TP53 P04637 2/20 0.46
GLA P06280 1/20 0.46
MAPK1 P28482 1/20 0.46
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
NTSR1 P30989 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013048 0.89 HPGD (0.65) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL2010800 0.86 HPGD (0.55) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL9080295 0.85 HPGD (0.53) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL2012737 0.85 HPGD (0.59) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL8603637 0.82 HPGD (0.50) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL2010455 0.81 HMGCR (0.53) HPGDHSD17B10NPSR1ALDH1A1MAPT
SCHEMBL3929739 0.80 PTPN1 (0.57) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL2037512 0.80 HPGD (0.59) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL7476409 0.79 HPGD (0.47) HPGDGAAHSD17B10KDM4ENPSR1
SCHEMBL2010507 0.79 GAA (0.59) HPGDGAAHSD17B10KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HPGD 1551/4885GAA 3340/4885HSD17B10 3132/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HPGD 1551/4885GAA 3340/4885HSD17B10 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.